• Users Online: 248
  • Print this page
  • Email this page
Year : 2021  |  Volume : 9  |  Issue : 3  |  Page : 107-112

Clinical profile of post-vaccination COVID-19-positive patients

1 Seven Hills Dedicated Covid Hospital, Mumbai, India
2 Department of Community Medicine, HBTMC and Dr RN Cooper Hospital, Mumbai, Maharashtra, India
3 Seven Hills Dedicated Covid Hospital, Mumbai, India; Department of Community Medicine, HBTMC and Dr RN Cooper Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Smita S Chavhan
Department of Community Medicine, HBTMC and Dr RN Cooper Hospital Mumbai, U 15, Bhaktivedanta Swami Road, JVPD Scheme, Juhu, Mumbai, Maharashtra 400056
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/dypj.dypj_44_21

Rights and Permissions

Background: Government of India launched the National COVID Vaccination Program with two vaccines, BBV152 (Covaxin) and AZD1222-ChAdOx1-S (Covishield). Both these vaccines have shown an efficacy of 78% and 63.1%, respectively, in clinical trials. It is evident that there still will be post-vaccination COVID-19-positive patients. However, there are no data regarding the severity and clinical profile of these vaccines in real world scenario. Hence, through this study, we aimed to assess clinical profile of patients of COVID-19 post-vaccination and evaluate the severity of the disease. Materials and Methods: This hospital-based cross-sectional study was done in a dedicated COVID Hospital with 1800 beds including 350 ICU beds after an Institutional Ethics Committee (IEC) approval. Confirmed COVID-19 RT–PCR-positive patients admitted to the DCH from March 10, 2021 to May 10, 2021 were asked history of vaccination and subjected to a predesigned standardized study proforma. Blood investigations were done at regular intervals. Regular standard of care was given to all patients. All cases post AZD1222 (Covishield) vaccine were categorized into two groups depending on the number of doses received and the data were statistically analyzed. Conclusion: As demonstrated by biochemical and radiological evaluation, two doses of the vaccine significantly reduced the severity of COVID-19 disease compared with a single dose, reducing the need for treatment interventions and also reducing the duration of hospitalization.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded25    
    Comments [Add]    

Recommend this journal